Group 1 - The core point of the announcement is that both Bozhou Junzefanglong and Huzhou Saihan have completed their share reduction plans as of December 9, 2025 [1] - Bozhou Junzefanglong reduced its holdings by 15.953 million shares, accounting for 1.70% of its total shares, with a total reduction amount of 173 million yuan, leaving a current holding percentage of 4.23% [1] - Huzhou Saihan reduced its holdings by 1.0117 million shares, representing 0.11% of its total shares, with a total reduction amount of 11.9752 million yuan, leaving a current holding percentage of 4.90% [1] Group 2 - The reduction plans were completed without early termination [1]

Group 1 - The core transaction on December 8 involved 1.2007 million shares of Zhenbao Island, with a total transaction value of 11.0223 million yuan, accounting for 14.61% of the total trading volume for the day [1] - The transaction price was 9.18 yuan, which represents a discount of 10.09% compared to the market closing price of 10.21 yuan [1] Group 2 - The trading data indicates that the shares were sold through various brokerage firms, with specific amounts and volumes recorded for each transaction [2] - The transactions were categorized under different types of trading departments, including institutional and company-specific trades [2]

Core Viewpoint - The company plans to provide a guarantee of up to RMB 400 million for its wholly-owned subsidiary, Bozhou Trading Center, to meet its bank financing needs, with the guarantee valid until the annual shareholders' meeting in 2025 [1][4]. Summary by Sections Guarantee Details - The company will provide a joint liability guarantee for Bozhou Trading Center's bank financing needs, totaling no more than RMB 400 million [1]. - The guarantee's effective period is from the approval date by the board until the 2025 annual shareholders' meeting [1]. Internal Decision-Making Process - The board of directors convened on December 5, 2025, to approve the guarantee proposal, which received majority support from the directors present [2]. - The proposal did not require shareholder meeting approval as it did not meet the threshold for such a review [2]. Basic Situation of the Guaranteed Party - As of the announcement date, Bozhou Trading Center has no significant issues affecting its debt repayment ability and is not classified as a dishonest executor [3]. Necessity and Reasonableness of the Guarantee - The guarantee is deemed necessary to support Bozhou Trading Center's operational needs, with the company maintaining good control over its subsidiary's credit status [4]. - The board believes the risks associated with the guarantee are manageable, and Bozhou Trading Center has sufficient capacity to repay its debts [4]. Cumulative Guarantee Situation - As of the announcement date, the company has a total external guarantee amount of RMB 1.755 billion, which is 22.50% of its latest audited net assets [4]. - The total guarantee for wholly-owned subsidiaries is RMB 1.555 billion, accounting for 19.93% of the latest audited net assets, while guarantees for joint ventures total RMB 200 million, or 2.56% of net assets [4]. - The company has not provided guarantees for controlling shareholders or related parties and has no overdue guarantees [4].

Company Overview - Zhenbaodao (SH 603567) announced that as of the disclosure date, the total amount of external guarantees provided by the company is RMB 1.755 billion, accounting for 22.5% of the latest audited net assets [1] - The total guarantees for wholly-owned subsidiaries amount to RMB 1.555 billion, representing 19.93% of the latest audited net assets [1] - The guarantees for associated companies total RMB 200 million, which is 2.56% of the latest audited net assets [1] Revenue Composition - For the year 2024, the revenue composition of Zhenbaodao is as follows: pharmaceutical manufacturing accounts for 87.78%, pharmaceutical commerce accounts for 11.13%, and other businesses account for 1.09% [1] Market Capitalization - As of the report, Zhenbaodao has a market capitalization of RMB 9.6 billion [1]

关于新增为全资子公司提供担保额度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | | 被担保人名称 | | 亳州中药材商品交易中心有限公司 | | | --- | --- | --- | --- | --- | | | 本次担保金额 | 40,000.00 | 万元 | | | 担保对象 | 实际为其提供的担保余额 | 33,500.00 | 万元 | | | | 是否在前期预计额度内 | □是 | ☑否 | □不适用：_________ | | | 本次担保是否有反担保 | □是 | ☑否 | □不适用：_________ | 累计担保情况 | 对外担保逾期的累计金额（万元） | 0 | | --- | --- | | 截至本公告日上市公司及其控股 子公司对外担保总额（万元） | 175,500 | | 对外担保总额占上市公司最近一 期经审计净资产的比例（%） | 22.50 | | 特别风险提示 | □对外担保总额（含本次）超过上市公司最 | | | 近一期经审计净资产 50% ...

2 2025.12.11 1 目录 | 2025 | 年第三次临时股东会会议须知 3 | | --- | --- | | 2025 | 年第三次临时股东会会议议程 4 | | 议案 | 1：关于续聘公司 2025 年度审计机构的议案 6 | 黑龙江珍宝岛药业股份有限公司 2025 年第三次临时股东会 会 议 资 料 黑龙江珍宝岛药业股份有限公司 2025 年第三次临时股东会会议须知 为维护全体股东的合法权益，确保股东会的正常秩序和议事效率， 根据《公司法》《上市公司股东会规则》《上海证券交易所上市公司 自律监管指引第1号——规范运作》及《公司章程》等相关规定，特 制定本次股东会须知如下： 一、会议按照法律、法规、有关规定和《公司章程》的规定进行， 参会人员应自觉维护会议秩序。 二、股东参加股东会，依法享有发言权、质询权、表决权等权利， 并应认真履行法定义务，不得侵犯其他股东的合法权益。 三、参会股东或股东代表应在2025年12月9日上午9时—11时，下 午14时—16时到黑龙江珍宝岛药业股份有限公司（以下简称"公司"） 或者通过电子邮件等形式办理参会登记。已办理参会登记的股东及股 东代表需携带身份证明、授权委 ...

Core Viewpoint - Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. has received a drug registration certificate for Moxifloxacin Hydrochloride Tablets, indicating an expansion in its product portfolio and enhancing its competitive position in the anti-infection market [1][4]. Drug Basic Information - The drug is Moxifloxacin Hydrochloride Tablets, with a specification of 0.4g and classified as a prescription drug [1]. - The drug registration certificate number is 2025S03558, and it is valid for 36 months, expiring on November 24, 2030 [1]. - The drug is approved for various infections, including acute bacterial sinusitis and community-acquired pneumonia [2]. Market and Financial Impact - Moxifloxacin Hydrochloride Tablets have been included in the National Basic Medical Insurance Directory for 2024, with a projected market size of 530 million RMB in China [3]. - The company has invested 13.64 million RMB in the research and development of this drug [3]. - There are currently 24 approved manufacturers for Moxifloxacin Hydrochloride Tablets in China [3]. Company Impact - The approval of Moxifloxacin Hydrochloride Tablets enhances the company's core product offerings in the anti-infection sector, thereby improving its market competitiveness [4]. - The company aims to broaden its business scope and strengthen its product matrix with this new addition [4].

Core Viewpoint - The company, Zhenbao Island (603567.SH), announced that its wholly-owned subsidiary, Harbin Zhenbao Pharmaceutical Co., Ltd., has received the drug registration certificate for Moxifloxacin Hydrochloride Tablets from the National Medical Products Administration, indicating a significant development in its pharmaceutical offerings [1] Group 1 - The approved drug is indicated for the treatment of various conditions including acute bacterial sinusitis, acute exacerbations of chronic bronchitis, community-acquired pneumonia, and several types of infections [1] - The drug is specifically approved for use in adults aged 18 and older, expanding the company's product portfolio in the pharmaceutical market [1] - The conditions treated by the drug include non-complicated and complicated skin and soft tissue infections, complicated intra-abdominal infections, plague, and mild to moderate pelvic inflammatory disease without associated tubo-ovarian or pelvic abscess [1]

Core Viewpoint - The company, Zhenbao Island (603567), has received approval from the National Medical Products Administration for its subsidiary Harbin Zhenbao Pharmaceutical Co., Ltd. to market Moxifloxacin Hydrochloride Tablets, indicating a significant advancement in its pharmaceutical offerings [1]. Group 1: Product Approval - The approved drug, Moxifloxacin Hydrochloride Tablets, is indicated for the treatment of various infections, including acute bacterial sinusitis, acute exacerbations of chronic bronchitis, community-acquired pneumonia, and several types of skin and intra-abdominal infections [1]. - The approval highlights the company's commitment to expanding its product portfolio in the pharmaceutical sector, particularly in addressing serious bacterial infections [1].

证券代码：603567 证券简称：珍宝岛 公告编号：临 2025-081 黑龙江珍宝岛药业股份有限公司 1 莫西沙星是具有广谱活性和杀菌作用的 8-甲氧基氟喹诺酮类抗菌药。莫西 沙星在体外显示出对革兰阳性菌、革兰阴性菌、厌氧菌、抗酸菌和非典型微生物 如支原体、衣原体和军团菌具有广谱抗菌活性。其杀菌作用机制为干扰拓扑异构 酶Ⅱ和Ⅳ。拓扑异构酶是控制 DNA 拓扑和在 DNA 复制、修复和转录中关键的酶。 莫西沙星表现为浓度依赖性的杀菌活性。最低杀菌浓度和最低抑菌浓度基本一致。 莫西沙星对β-内酰胺类和大环内酯类耐药的细菌亦有效。通过感染的实验动物 模型证实，莫西沙星体内活性高。 盐酸莫西沙星片（商品名：Avelox ®）由 Bayer Vital GmbH 研发并于 1999 年在德国首次上市，2002 年盐酸莫西沙星片（商品名：拜复乐）在中国上市。 用于治疗成人（≥18 岁）急性细菌性鼻窦炎、慢性支气管炎急性发作、社区获 得性肺炎、非复杂性皮肤和皮肤组织感染、复杂性皮肤和皮肤组织感染、复杂性 腹腔内感染、鼠疫、不伴有输卵管-卵巢或盆腔脓肿的轻至中度盆腔炎性疾病。 关于全资子公司获得药品注册证书的公告 本公司董 ...